Zheng MJ, Li X, Hu YX, Dong H, Gou R, Nie X, Liu Q, Ying-Ying H, Liu JJ, Lin B. Identification of molecular marker associated with ovarian cancer prognosis using bioinformatics analysis and experiments. J Cell Physiol. 2019;234(7):11023–36.

Article  CAS  PubMed  Google Scholar 

Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J. Karlan B Y. ovarian cancer. Nat Reviews Disease Primers. 2016;2:16062.

Article  Google Scholar 

Ghisoni E, Imbimbo M, Zimmermann S, Valabrega G. Ovarian Cancer immunotherapy: turning up the heat. Int J Mol Sci. 2019;20(12):2927.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ventriglia J, Paciolla I, Pisano C, Cecere SC, Napoli M, Tambaro R, Califano D, Losito S, Scognamiglio G. Setola S V. Immunotherapy in ovarian, endometrial and cervical cancer: state of the art and future perspectives. Cancer Treat Rev. 2017;59:109–16.

Article  CAS  PubMed  Google Scholar 

Drakes ML, Stiff PJ. Regulation of Ovarian Cancer Prognosis by Immune cells in the Tumor Microenvironment. Cancers. 2018;10(9):302.

Article  PubMed  PubMed Central  Google Scholar 

Tu L, Guan R, Yang H, Zhou Y, Hong W, Ma L, Zhao G, Yu M. Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival. Int J Cancer. 2020;147(2):423–439.

Zeng Y, Li B, Liang Y, Reeves PM, Qu X, Ran C, Liu Q, Callahan MV, Sluder AE, Gelfand JA, Chen H, Poznansky MC. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment. FASEB J. 2019;33(5):6596–608.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wall JA, Meza-Perez S, Scalise CB, Katre A, Londono AI, Turbitt WJ, Randall T, Norian LA, Arend RC. Manipulating the Wnt/beta-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy. Gynecol Oncol. 2021;160(1):285–94.

Article  CAS  PubMed  Google Scholar 

Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.

Article  Google Scholar 

Varga A, Piha-Paul S, Ott PA, Mehnert JM, Berton-Rigaud D, Morosky A, Yang P, Ruman J. Matei D. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028. Gynecol Oncol. 2019;152(2):243–50.

Article  CAS  PubMed  Google Scholar 

Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin G, Kaye SB, Hirte H, Eisenhauer E. Vaughan M. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;387(10023):1066–74.

Article  CAS  PubMed  Google Scholar 

Wan C, Keany MP, Dong H, Al-Alem LF, Hill SJ. Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high grade serous ovarian cancer. Cancer Res. 2020;81(1):158–73.

Article  PubMed  PubMed Central  Google Scholar 

Xue C, Xu Y, Ye W, Xie Q, Gao H, A B X, Zhang D, Jiang J. Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor. Gynecol Oncol. 2020;157(1):222–33.

Article  CAS  PubMed  Google Scholar 

Tan D, Sheng L, Yi QH. Correlation of PD-1/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancer. Cancer Biomark. 2018;21(2):287–97.

Article  CAS  PubMed  Google Scholar 

Zhou Q, Yan X, Liu W, Yin W, Ren C. Three Immune-Associated subtypes of diffuse glioma Differ in Immune Infiltration, Immune Checkpoint molecules, and prognosis. Front Oncol. 2020;10:586019.

Article  PubMed  PubMed Central  Google Scholar 

Musacchio L, Cicala CM, Camarda F, Ghizzoni V, Giudice E, Carbone MV, Ricci C, Perri MT, Tronconi F, Gentile M, Salutari V, Scambia G. Lorusso D. combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? ESMO Open. 2022;7(4):100536.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maiorano BA, Lorusso D, Maiorano MFP, Ciardiello D, Parrella P, Petracca A, Cormio G. Maiello E. The interplay between PARP inhibitors and Immunotherapy in Ovarian Cancer: the Rationale behind a New Combination Therapy. Int J Mol Sci. 2022;23(7).

Petitprez F, Meylan M, Reyniès A, d, Sautès-Fridman C. Fridman W H. The Tumor Microenvironment in the response to Immune Checkpoint Blockade therapies. Front Immunol. 2020;11:784.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scaletta G, Plotti F, Luvero D, Capriglione S, Montera R, Miranda A, Lopez S, Terranova C, Carlo DCN, Angioli R. The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review. Expert Rev Anticancer Ther. 2017;17(9):827–39.

Article  CAS  PubMed  Google Scholar 

Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-Mccune K, Broaddus R, Lu KH, Chen J. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012;107(10):1776–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Birkbak NJ, Wang ZC, Kim J-Y, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozz A. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012;2(4):366–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andrea M, Marquard, Aron C, Eklund. Tejal, Joshi, Marcin, Krzystanek, Francesco,Favero. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res. 2015;1(3):9.

Google Scholar 

Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN. Kamińska B,Huelsken J. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell. 2018;173(2):338–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

El Bairi K, Afqir S, Amrani M. Is HE4 Superior over CA-125 in the follow-up of patients with epithelial ovarian Cancer? Curr Drug Targets. 2020;21(10):1026–33.

Article  PubMed  Google Scholar 

Deng J, Wang L, Chen H, Li L, Ma Y, Ni J, Li Y. The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression. Cancer Metastasis Reviews. 2013;32(3–4):535–51.

Article  CAS  PubMed  Google Scholar 

Samstein RM, Lee C-H, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ. Omuro A,Kaley T J. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lmsa B, Frhc D, Hwang ED, Botling FJ, Lopez-Rios FF, Lb H, Mk I, Acr J, Mbb D, Ab K. The promises and challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: a perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2020;15(9):1409–24.

Article  Google Scholar 

Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, Miller VA, Lim D. Amanam I,Chao J. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019;30(7):1096–103.

Article  CAS  PubMed  Google Scholar 

Solinas C, Marcoux D, Garaud S, Vitória J, Gert V, Wind AD, Silva PD, Boisson A, Craciun L. Larsimont D. BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer. Cancer Lett. 2019;450:88–97.

Article  CAS  PubMed  Google Scholar 

Shim JH, Hong SK, Cha H, Kim S, Lee SH. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small–cell lung cancer patients. Ann Oncol. 2020;31(7):902–11.

Article  CAS  PubMed  Google Scholar 

Luo Y, Xia Y, Liu D, Li X, Li H, Liu J, Zhou D, Dong Y, Li X, Qian Y, Xu C, Tao K, Li G, Pan W, Zhong Q, Liu X, Xu S, Wang Z, Liu R, Zhang W, Shan W, Fang T, Wang S, Peng Z, Jin P, Jin N, Shi S, Chen Y, Wang M, Jiao X, Luo M, Gong W, Wang Y, Yao Y, Zhao Y, Huang X, Ji X, He Z, Zhao G, Liu R, Wu M, Chen G, Hong L, Consortium C, Ma D, Fang Y, Liang H, Gao Q. Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell. 2024;187(18):4905–25. e24.

Article  CAS